Evidence map›Paper›PMID 41540233›Full record

ArticleCommunications biology2026

Epigenetic and metabolic rewiring in metastatic pheochromocytomas and paragangliomas driven by SDHB mutations.

Tamara Cubiella, Juan José Alba-Linares, Jaime San-Juan-Guardado, Alvaro Suarez-Priede, Nerea Gómez-Suárez, Maria Tous, Irina Bancos, Carles Villabona, Teresa Serrano, Isabel Tena and 5 more

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tamara Cubiella *Institute of Oncology of Principality of Asturias, Universidad de Oviedo, Oviedo, Spain.
Juan José Alba-Linares *Institute of Oncology of Principality of Asturias, Universidad de Oviedo, Oviedo, Spain.
Jaime San-Juan-GuardadoInstitute of Oncology of Principality of Asturias, Universidad de Oviedo, Oviedo, Spain.ORCID http://orcid.org/0000-0001-9177-9408
Alvaro Suarez-PriedeInstitute of Oncology of Principality of Asturias, Universidad de Oviedo, Oviedo, Spain.
Nerea Gómez-SuárezInstitute of Oncology of Principality of Asturias, Universidad de Oviedo, Oviedo, Spain.
Maria TousUnidad de Gestión Clínica of Endocrinology and Nutrition, Hospital Virgen Macarena, Seville, Spain.ORCID http://orcid.org/0009-0001-6891-0671
Irina BancosDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
Carles VillabonaService of Endocrinology and Nutrition, Hospital Universitario de Bellvitge, Barcelona, Spain.
Teresa SerranoService of Pathology, Hospital Universitario de Bellvitge, Barcelona, Spain.
Isabel TenaService of Medical Oncology, Hospital Provincial de Castellón, Castellón, Spain.
Maribel Del OlmoService of Endocrinology and Nutrition, Hospital Universitario La Fe, Valencia, Spain.
Lluis ForgaService of Endocrinology and Nutrition, Complejo Universitario de Navarra, Pamplona, Spain.
Nuria ValdésEndocrinology and Nutrition Department, Hospital Universitario Cruces, Biobizkaia, UPV/EHU, CIBERDEM, CIBERER, Endo-ERN, Barakaldo, Bizkaia, Spain.ORCID http://orcid.org/0000-0001-5859-257X
Mario F FragaInstitute of Oncology of Principality of Asturias, Universidad de Oviedo, Oviedo, Spain.ORCID http://orcid.org/0000-0001-8450-2603
María-Dolores ChiaraInstitute of Oncology of Principality of Asturias, Universidad de Oviedo, Oviedo, Spain. mdchiara.uo@uniovi.es.ORCID http://orcid.org/0000-0002-1112-1583

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pheochromocytomas and paragangliomas (PPGLs) with SDHB mutations frequently develop metastases, but the molecular mechanisms driving this progression remain unclear. Here we show that SDHB-mutant metastatic PPGLs display an amplified hypermethylation signature, particularly in genes involved in neuronal differentiation, building on previous findings in SDHx-mutated tumors. This epigenetic shift is already detectable in benign SDHB-mutant tumors, suggesting early priming toward a less differentiated state. In parallel, we identify hypomethylation of genes linked to carbohydrate metabolism, notably the fructose transporter SLC2A5. Functional assays reveal that SDHB loss, hypoxia, exogenous succinate, and fructose availability promote tumor cell growth and induce cell-type-restricted, SDHB-dependent, induction of SLC2A5 expression. These findings highlight the dual role of SDHB mutations in driving epigenetic reprogramming and metabolic adaptation, promoting tumor cell plasticity and survival under metabolic stress. By uncovering a fructose-driven metabolic vulnerability, our study provides insights into the molecular mechanisms underlying metastatic PPGLs and identifies potential therapeutic targets at the intersection of epigenetic and metabolic regulation.

Indexed as

Adrenal Gland NeoplasmsEpigenesis, GeneticMutationParagangliomaPheochromocytomaSuccinate DehydrogenaseAnimalsCell Line, TumorDNA MethylationGene Expression Regulation, NeoplasticGlucose Transporter Type 5HumansMetabolic ReprogrammingGlucose Transporter Type 5SDHB protein, humanSLC2A5 protein, humanSuccinate Dehydrogenase

Identifiers

PMID41540233
PMCPMC12913883

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.